Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Calimmune

Calimmune
2006 FOUNDED
M&A STATUS
31-40 EMPLOYEES
M&A LATEST DEAL TYPE
$416M LATEST DEAL AMOUNT
Description

Developer of a gene modification and cell delivery technology designed to translate the promise of gene therapy into effective and accessible products that have the power to restore health and improve lives. The company's gene modification and cell delivery technology works by genetically modifying patients' own cells to shield and strengthen their immune system and create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable diseases, enabling physicians to address the unique needs of individuals at different stages of HIV infection and with various treatment histories.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Primary Office
  • 5151 East Broadway Boulevard
  • Suite 1020
  • Tucson, AZ 85711
  • United States

+1 (310) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Calimmune’s full profile, request a free trial.

Calimmune Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 11-Sep-2017 $416M 000.00 00000 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 27-May-2015 000.00 000.00 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 01-Dec-2013 000 00.000 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC 16-Sep-2011 000 00.000 Completed Generating Revenue
2. Angel (individual) 01-Jun-2010 $50K $50K Completed Startup
1. Grant $8.28M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Calimmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 0,000,000 00.000000 00 000.0 000.0 00 000.0 0.000
Series A 0,000,000 00.000000 00 000.0 000.0 00 000 00.000
Series 4 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 3 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series 2 107,000 $0.001000 8% $4.94 $4.94 1x $4.94 0.85%
Series 1 188,136 $0.001000 8% $5 $5 1x $5 1.49%
To view this company’s complete Cap Table, request access »

Calimmune Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ViaCyte Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 00000000 00000
00000000 Venture Capital-Backed Tübingen, Germany 00 00000 00000000000 00000
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
000000 Venture Capital-Backed Lebanon, NH 000 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Calimmune Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
California Institute for Regenerative Medicine Government 000 0000 000000 0
Cycad Group Venture Capital Minority 000 0000 000000 0
DVI Equity Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Calimmune Executive Team (14)

Name Title Board
Seat
Contact
Info
Louis Breton Co-Founder, Chief Executive Officer & Board of Director
Jeffrey Bartlett Ph.D Chief Scientific Officer
James Sullivan Ph.D Director
Inder Verma Ph.D Co-Founder & Scientific Advisor
Irvin Chen Ph.D Co-Founder & Scientific Advisor

2 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Calimmune Board Members (8)

Name Representing Role Since Contact
Info
David Baltimore Ph.D Self Co-Founder & Co-Chairman 000 0000
Harry George III Self Board Member 000 0000
Jon Faiz Kayyem Ph.D Calimmune Board Member and Co-Founder 000 0000
Louis Breton Calimmune Co-Founder, Chief Executive Officer & Board of Director 000 0000
Scott Greer Self Co-Chairman 000 0000

3 Former Board Members

You’re viewing 5 of 8 board members. Get the full list »